Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited (CNTB) Revenue
Annual & quarterly revenue history · segment & region breakdown
CNTB · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsConnect Biopharma Holdings Limited trailing twelve-month (TTM) revenue is $0.02B, a decrease of 99.75% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.03B | -99.75% |
| 2024-12-31 | $0.03B | +$0.03B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Connect Biopharma Holdings Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Connect Biopharma Holdings Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Connect Biopharma Holdings Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CNTB revenue · 4 questionsCNTB's trailing twelve-month (TTM) revenue is $0.02B. That is a decrease of 99.75% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Connect Biopharma Holdings Limited SEC filings · GAAP · Connect Biopharma Holdings Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026